|
Mutation Information
|
Mutation Site
|
Y115F |
|
Mutation Type
|
Amino acid level |
|
Gene/Protein/Region Type
|
RT |
|
Combined Mutation
|
rt.Q151M+rt.F116Y+rt.Y115F;rt.M184V+rt.Q151M+rt.F116Y+rt.Y115F;rt.M184V+rt.F160M+rt.Q151M+rt.F116Y+rt.Y115F;rt.M184V+rt.Q182G+rt.F160M+rt.Q151M+rt.F116Y+rt.Y115F;rt.F160L+rt.Q151M+rt.F116Y+rt.Y115F+rt.D113A+rt.G112S;rt.F160L+rt.Q151M+rt.V118L+rt.F116Y+rt.Y115F+rt.D113A+rt.G112S |
|
Relevant Drug
|
entecavir (ETV);lamivudine (LAM);tenofovir alafenamide (TAF);islatravir (ISL);zidovudine (AZT) |
Literature Information
|
PubMed PMID
|
32080249
|
|
Published Year
|
2020 |
|
Journal
|
Scientific reports |
|
Title
|
Structural features in common of HBV and HIV-1 resistance against chirally-distinct nucleoside analogues entecavir and lamivudine. |
|
Author
|
Yasutake Y,Hattori SI,Tamura N,Matsuda K,Kohgo S,Maeda K,Mitsuya H |
|
Evidence
|
Here, we show that human immunodeficiency virus type-1 (HIV-1) with HBV-associated amino acid substitutions Y115F/F116Y/Q151M in its RT (HIVY115F/F116Y/Q151M) is highly susceptible to ETV and 3TC.
|
|
|
HIV Mutation Detail Information